VEGFC and neoplasm: CCL19 or CCL21 binding to CCR7 activates signaling pathways in tumor cells, including PI3/Akt [264-266], MAPK/ERK [267-269], and Jak/STAT [269, 270], thereby enhancing VEGF-C expression.